Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

Lilly adds gene delivery technology to CAR T in up to $7B Kelonia deal

 April 20, 2026

BioSpace

After entering the CAR T space in February, Eli Lilly is “jumping into in vivo CAR-T with both feet” with the acquisition of Kelonia Therapeutics and its gene delivery technology.

M&A / DealsGene Therapy PlatformRead full story

Post navigation

Novo’s late-stage sickle cell win piles pressure on competitors →
← Boehringer Ingelheim launches AI centre in London

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com